IV Ketamine for Depression: What the Infusions Do, What the Trials Show, and How It Compares With Spravato

The claims arrive before the evidence does. Ketamine resets the brain. It rewires depression. It grows new connections. Those sentences are doing a great deal of work for something the FDA has never approved for depression at all. Here is what is actually documented — and where the documentation stops.

Disclosure, before you read further

• Inland Psychiatric Medical Group, where I practice, offers Spravato. It does not offer IV ketamine. So this article covers a treatment we do not provide, while we do provide the alternative it is most often compared against. That conflict points in a specific direction, and you deserve to know it before you read a single line of comparison.

• I have handled it the only way I know how. Every claim on both sides is cited to a primary source. The ketamine trials that failed are in here alongside the ones that worked. And the comparison section says plainly what the evidence says: no completed randomized trial establishes either treatment as better than the other. If you find a place where this reads as tilted, check it against the sources at the end.

What to know

• IV ketamine for depression is off-label. Ketamine injection is FDA approved as a general anesthetic. There is no FDA-approved psychiatric dose, infusion count, or maintenance schedule — and that is not a technicality, it is the reason protocols differ so much between clinics.[1]
• The short-term evidence is real. Randomized trials, including ones using the harder-to-guess midazolam comparator, show an average symptom drop within hours to a day in carefully selected adults with treatment-resistant depression.[2,3,4,5,6]
• The negative trials are real too. KARMA-Dep2, a 2025 randomized trial of repeated infusions, did not find a significant benefit over midazolam.[10]
• Relapse is common. In small follow-up studies, many responders relapsed within days to weeks after an acute series. No maintenance schedule has been established.[9,11,12]
• It has not been shown to prevent suicide. Some trials found short-term drops in suicidal-ideation scores. That is a different claim from preventing attempts or deaths, and the trials were far too small to test the second one.[13,14,15,16]
• The 2026 injection label carries warnings you should know about, covering liver and bile-duct injury and urinary tract damage with repeated use — along with specific blood tests to run before and during a course.[1]

The short answer

Racemic ketamine is a roughly equal mix of two mirror-image forms of the same molecule, R and S. It is given into a vein, usually over about 40 minutes.

The injection has been FDA approved since 1970 — as an anesthetic. Using it for depression is lawful off-label prescribing, which is ordinary medicine and not a loophole. But off-label means the FDA has never reviewed and approved a dose, a schedule, a number of infusions, or a maintenance plan for depression. Every one of those decisions is being made by the clinic in front of you.[1,19]

The evidence is strongest for short-term symptom relief in carefully selected adults with unipolar treatment-resistant depression. Group averages can improve within hours to a day. Not everyone responds. Relapse is common. And ketamine is a Schedule III controlled substance, with real risks of misuse and dependence.[1,20]

What IV racemic ketamine actually is — and what it is not

This distinction matters more than almost anything else on this page, because the word “ketamine” is now attached to at least six different products that share almost no evidence with one another.

Evidence for any one of these is not evidence for the others. If a clinic cites a famous IV trial while selling you sublingual lozenges, that is a category error — and a common one.

A clinic using IV ketamine may well be using an FDA-approved sterile injection product off-label, diluted for infusion per the label rather than compounded. IV ketamine is not automatically a compounded product.[1,33] But you are entitled to ask which it is.

For the nasal-spray product and its own separate evidence base, see the full Spravato guide.

Where the known science stops

Ketamine blocks NMDA receptors — the receptors that glutamate, the brain’s main excitatory messenger, acts on. Norketamine, an active metabolite, acts at the same receptors but binds less strongly. That much is documented pharmacology.[1,18]

Everything after that is proposal.

The standard story goes: brief changes in glutamate release, then increased AMPA-receptor signaling, then BDNF and mTOR, then new protein production and synaptic plasticity, then shifts across whole brain networks. It is a coherent chain, and much of it was built in rodents and cell cultures. Human imaging and drug-interaction studies do provide real evidence for individual steps — but no one has demonstrated the whole pathway in people.[18,24]

Studies of whether the opioid system is involved are few, small, and conflicting; a 2026 systematic review concluded it is more likely a context-dependent modulator than a primary mediator at standard antidepressant doses.[28]

So when marketing says ketamine resets, rewires, heals, or grows new connections in a human brain — those are claims running well ahead of what anyone has demonstrated.[18,24]

Zoom

What the body does with it

Because it goes straight into a vein, bioavailability is 100% by definition. During a timed infusion, blood levels are highest near the end, and the drug then moves rapidly into tissue. The label describes an early distribution phase of about 45 minutes with a half-life of 10 to 15 minutes, then a slower phase with a half-life of about 2.5 hours.[1]

Ketamine is roughly 10% to 30% protein bound and distributes widely into well-perfused tissue, with a reported steady-state volume of distribution of about 3 to 5 liters per kilogram — roughly 160 to 550 liters in a 70-kilogram adult. Reported systemic clearance is roughly 14 to 35 milliliters per minute per kilogram, which approaches liver blood flow. All of these vary by study, dose, age, illness, and setting.[18,25]

CYP2B6 and CYP3A4 convert ketamine mainly into norketamine, which becomes hydroxynorketamines and dehydronorketamine before being cleared, mostly in urine. The label offers no validated psychiatric dose adjustment for liver or kidney impairment, and there is no proven blood-level target that predicts response.[1,18,25]

Here is the part worth carrying out of this section: half-life predicts when the drug wears off — and nothing else. It governs the monitoring window, the recovery period, and the 24-hour driving restriction. It does not tell you when mood will improve, how many infusions you will need, or whether there will be any benefit at all.

The numbers make the point. Ketamine is undetectable in blood within about a day of a 0.5 mg/kg infusion — yet group-level symptom differences have been measured at Day 3 and at one week.[6,18] Other people get no benefit at all from the same protocol.

Who needs a careful evaluation first

A good evaluation looks backward before it looks forward.

Confirm the diagnosis, then interrogate the “resistance.” The term treatment-resistant often turns out to describe something else — what clinicians call pseudo-resistance. Missed bipolar disorder. Untreated sleep apnea. Doses never taken. Thyroid disease. Alcohol. A medication trial that ran four weeks instead of eight.[21,22] If any of those is the real story, an infusion is the wrong door. Why antidepressants take time covers what an adequate trial looks like, and why bipolar disorder gets called depression first covers the diagnostic miss that matters most here.

The psychiatric review should cover mania or hypomania, psychosis, dissociation, trauma, panic, cognitive problems, substance use, overdose history, self-harm, and current suicide risk.

The medical review should cover blood pressure, heart rhythm, heart failure, vascular and cerebrovascular disease, airway and breathing risk, liver and bile-duct disease, urinary symptoms, kidney function, pregnancy, and breastfeeding.[1,21,26]

The medication review is not optional. The label states that opioids, benzodiazepines, alcohol, and other CNS depressants may cause profound sedation, respiratory depression, coma, and death when combined with ketamine — and calls for close neurologic and respiratory monitoring, including respiratory rate and pulse oximetry. Opioids may also prolong the time to complete recovery from anesthesia — whether that extends to a subanesthetic depression infusion has not been established. The label calls for close vital-sign monitoring with sympathomimetics or vasopressin, and says to consider a dose adjustment individualized to the patient. And it says not to use theophylline or aminophylline with Ketalar, because the combination may lower the seizure threshold.[1]

One interaction deserves its own line, because patients are rarely told about it. A systematic review of small, low-quality studies found that benzodiazepines repeatedly shortened the duration of ketamine’s antidepressant effect, and that lamotrigine may blunt it. Naltrexone studies are mixed.[27,28]

Do not stop any medicine to prepare for an infusion without the clinician who prescribed it.

Off-label consent should cover the evidence, the alternatives, the uncertainty, what the acute experience is like, the product source, the monitoring plan, the total cost, and how treatment would stop.

What an infusion visit looks like

Most research used 0.5 mg/kg over about 40 minutes. Some trials compared lower and higher doses. Repeated-infusion studies often used two or three infusions weekly for two to four weeks.[4,5,7,8]

Those are research examples. They are not FDA instructions and not a universal standard.

A visit typically begins with checks of symptoms, suicide risk, medications, substance use, and vital signs — sometimes labs or cardiac testing depending on risk. Staff place an IV and start the timed infusion. In common psychiatric protocols you stay awake, though attention, perception, and speech may change. Monitoring continues through recovery.

The label itself sets a high bar for who administers this drug. It says ketamine should be given by, or under the direction of, physicians experienced in administering general anesthetics and in maintaining a patent airway, oxygenation, and ventilation. It directs continuous vital-sign monitoring, and states that emergency airway equipment must be immediately available.[1]

Those are anesthesia-label requirements rather than a depression protocol — but they describe the drug you are receiving. Psychiatric consensus adds a qualified mental-health assessment, oxygen and cardiac monitoring, trained staff, rescue skills, defined recovery criteria, and a transfer plan.[21,26,29]

Driving. The injection label says not to drive, operate hazardous machinery, or engage in hazardous activity for 24 hours. You need a ride. Feeling normal sooner is not a reason to drive.[1]

How fast, and how long

Trials have measured group-average differences at 40 minutes, four hours, and 24 hours. A 2026 meta-analysis of 26 randomized trials and 1,166 patients favored ketamine after a single infusion at four hours, 24 hours, Day 3, and one week. The pooled confidence intervals were wide, and the included trials differed in design.[6]

That is a group average, not a personal forecast. “Response” usually means at least a 50% drop on a symptom scale, but trials use different scales and different rules. “Remission” means a low score at a set time. Neither guarantees restored function or lasting wellness.

And on durability: in small follow-up studies, relapse often came within days to weeks after an acute series. Some responders stayed well much longer. Repeated or maintenance treatment may extend benefit, but the best interval, total duration, and stopping rule have not been established.[9,11,12]

What one infusion showed

The first randomized report, in 2000, included seven people. It opened a research question rather than answering one.[2]

In 2006, a saline-controlled crossover trial gave ketamine to 17 adults with treatment-resistant major depression. At 24 hours, 12 of 17 (71%) met the response definition and 5 of 17 (29%) met remission. About 35% held a response for at least a week.[3] Tiny, highly selected, and — because saline hides nothing — easy to guess.

The stronger study randomized 73 adults against midazolam, an active comparator that mimics some sedation and is harder to see through.

That is the most credible single-infusion result in the field.[4] Even so, dissociation can still reveal the assignment.

The NIMH-funded dose-ranging trial randomized 99 adults. After adjustment for multiple comparisons, the 0.5 and 1.0 mg/kg groups improved more than midazolam on Day 1. Lower doses were not consistently positive. No dose remained significantly different by Day 3 after adjustment. And clinicians correctly guessed nearly every high-dose assignment — a plain demonstration of how hard blinding is here.[5]

Together these support a short-term average effect. They do not establish an optimal dose, routine longer-term benefit, or an individual’s chance of responding in an ordinary clinic. Work, caregiver burden, and hospital use were mostly not measured at all.

What repeated infusions showed

A 68-person saline-controlled study found that both the twice-weekly and three-times-weekly ketamine groups improved more by Day 15 — response in 68.8% and 53.8% respectively. The trial was not large enough to say which schedule was better. It used saline, and it was industry-funded.[7]

In an open six-infusion series, 17 of 24 people (70.8%) responded — with no control group and close follow-up in selected patients.[9] Another study of 41 people randomized the first infusion against midazolam and then opened the series to everyone: response 59%, remission 23%, median time to response three infusions.[8]

And then there is KARMA-Dep2, which belongs in any honest account.

It randomized 65 hospitalized adults with unipolar or bipolar major depressive episodes to up to eight ketamine or midazolam infusions plus usual care. The MADRS difference favored ketamine by 3.16 points — but the 95% confidence interval ran from an 8.54-point advantage to a 2.22-point disadvantage, with p=0.25. Quality of life did not differ.[10]

The trial was underpowered relative to its own plan, mixed diagnoses, and was not a pure outpatient treatment-resistant depression study. Those are real limitations. But the finding stands: repeated infusions are not uniformly positive.

Taken as a whole, repeated infusions can extend acute improvement during a series. Certainty is moderate for an average short-term effect and low for the exact response rate, the best frequency, and what happens in ordinary practice.[6]

Maintenance: the thinnest part of the evidence

Small studies have offered weekly or less frequent infusions to people who responded first. In the Phillips study, selected responders stayed improved across four weekly infusions — open-label, small, and only four weeks long.[8] In another open series, among the 17 people who responded, the median time to relapse was 18 days after the last infusion — and four had still not relapsed when the 83-day follow-up ended.[9]

A 2022 review of maintenance treatment found three randomized trials, eight open-label studies, and a scattering of case reports across multiple formulations and routes. Samples, schedules, and controls varied too much to define any standard.[11]

There is no FDA-approved maintenance regimen for depression.[1] A clinic should be able to tell you, before you start, when it would continue, when it would lengthen intervals, when it would stop for lack of benefit, and what happens if you relapse.

What the evidence does not show is that open-ended treatment restores work, prevents hospitalizations, protects caregivers, or remains safe indefinitely for everyone.

If you are in danger right now

• If you may act on suicidal thoughts, or you cannot keep yourself safe, call 911 or go to the nearest emergency department.

• In the United States, call or text 988 for the Suicide & Crisis Lifeline.

• Neither IV ketamine nor Spravato replaces urgent evaluation or a hospital stay when one is needed.[30]

Ketamine and suicidal thoughts

This is the area where the gap between what was measured and what people hear is widest.

A midazolam-controlled trial of 80 adults with major depression. On Day 1, the Scale for Suicidal Ideation fell 4.96 points more with ketamine (95% CI 2.33 to 7.59). A drop of 50% or more occurred in 55% versus 30%.[13]

A French inpatient trial of 156 people, who received two 40-minute infusions of ketamine 0.5 mg/kg or saline — one at baseline and one 24 hours later — on top of usual inpatient care. At Day 3, suicidal ideation remitted in 46 of 73 ketamine patients versus 25 of 79 on placebo. But the bipolar subgroup drove that result; the major-depression subgroup was not statistically positive. Through six weeks, suicide attempts occurred in 6 of 73 and 8 of 82. One person in the ketamine arm died by suicide, which the trial’s oversight committee judged unrelated to the study drug. The trial was nowhere near large enough to test effects on attempts or deaths.[14]

A negative trial. Twenty-six adults with severe treatment-resistant depression and chronic suicidal ideation received six ketamine or saline infusions. No significant difference in depression (p=0.47) or suicidal ideation (p=0.32).[15]

And the pooled analysis. Individual participant data from 10 controlled trials, narrowed to the 167 people who had suicidal thoughts at baseline, found ketamine lowered ideation ratings within a day, with moderate-to-large effect sizes through one week — and that this was only partly explained by the change in depression severity.[16]

That pooled analysis is the strongest evidence on this page. And it is still measuring rating scales over hours to days — as is everything above it. None of these studies demonstrates fewer suicide attempts, fewer deaths, or fewer emergency visits. Ketamine does not replace an emergency assessment, a safety plan, a hospital stay when one is needed, or ongoing care. If you are weighing this during a crisis, urgent mental health care covers what to do now.

Bipolar depression and other populations

Two small crossover trials — 18 and 15 adults with treatment-resistant bipolar depression — added a single infusion for people already maintained at therapeutic blood levels of lithium or valproate. Note that phrase: the trials required documented therapeutic-range monitoring, not simply a standard dose.

Short-term response was much more common with ketamine in both — 71% versus 6%, and 79% versus 0%. But these were 18 and 15 people, everyone was already on a mood stabilizer, and follow-up ran only 14 days. In the larger trial, one participant developed manic symptoms after ketamine and one after placebo — symptoms, not a diagnosed manic episode.[23,31]

Neither of those trials tested repeated or maintenance dosing, so the evidence for that in bipolar depression is thinner still. Mania, cycling, and psychosis need active monitoring.[21] These findings should not be merged with unipolar treatment-resistant depression data.

Data are thin for older and younger adults, for pregnancy and breastfeeding, for significant liver or kidney disease, primary psychotic disorders, active substance-use disorders, and complex cardiac, vascular, or cerebrovascular disease. Trials generally excluded these groups.

On pregnancy specifically: human data come mostly from cesarean-delivery anesthesia and are too limited to assess risk outside that setting. Animal studies show developmental and neurotoxicity signals whose clinical meaning is unclear. Ketamine and its metabolites do enter human milk; the label limits lactation guidance to anesthesia and advises monitoring the infant for sedation, respiratory depression, increased muscle tone, or spasms.[1]

What the evidence cannot tell us

Blinding is the field’s structural weakness. Saline hides essentially nothing. Midazolam helps, but it does not reproduce ketamine’s effects on perception. Patients and raters can often guess correctly, which inflates expectancy and measurement bias.[5,10]

Trial populations are narrow. Study exclusions remove many of the people who actually walk into clinics.

Protocols vary on nearly every axis — dose, infusion rate, number of treatments, concurrent medications, rating scale, and follow-up length. Positive and non-positive findings coexist. Publication bias remains possible.

Almost everything measured is a symptom score. Evidence is thin for durable quality of life, work, caregiver burden, relationships, hospital use, suicide attempts, and mortality. Maintenance evidence is weakest of all.

What an infusion feels like

Detached from your body. Light, dreamy, slowed, numb, dizzy, or anxious. Time or the room may seem altered. Vision may blur, speech may slow, balance may worsen. Some people have nausea, vomiting, headache, or a frankly frightening shift in perception.[1,6,17]

Blood pressure and heart rate commonly rise for a while. At the subanesthetic doses used in depression research, dissociative and sedative effects are common but usually resolve within one to two hours of the infusion.[6,17] A depression infusion is generally not aiming for unconsciousness — but deep sedation and serious medical effects remain possible, and risk rises with other depressants, rapid dosing, a dosing error, or medical illness.[1]

One thing to be clear about: dissociation is listed as an adverse effect. Whether the intensity of the experience predicts antidepressant benefit is genuinely unsettled in the ketamine literature — which is exactly why a clinic should not market an intense experience as proof the treatment is working.

Serious risks

Heart, breathing, and brain

The label reports common increases in blood pressure, heart rate, and cardiac output — and also low blood pressure, slow heart rate, arrhythmias, and worsening cardiac function. Rapid injection or overdose can depress breathing. Increased intracranial pressure has been reported. Monitoring and rescue capacity matter even at psychiatric doses.[1]

Mania, psychosis, thinking, and misuse

Ketamine can cause emergence reactions, hallucinations, agitation, or confusion. Mania and psychosis appear uncommon in trials, but rates are poorly measured in higher-risk patients.[1,23]

On memory and attention, be careful which finding you are reading. The label’s warning is about recurrent high-dose misuse or abuse, which it links to memory and attention impairment — not about supervised dosing.[1] The 2026 long-term safety review, looking at therapeutic use, identified no treatment-emergent neurocognitive dysfunction.[17] Acute changes in attention during and shortly after an infusion are well described clinically, but they are not well quantified in these trials, and long-term cognitive effects in supervised depression care remain uncertain.

Misuse, tolerance, physical dependence, and addiction are all possible. Label reports of withdrawal largely followed frequent high-dose use over long periods — those rates do not transfer directly to monitored infusions. But repeated treatment still calls for ongoing checks on substance use and dose escalation.[1]

Bladder and liver — the risks most often left out of the sales pitch

The March 2026 label links repeated use — explicitly including medically supervised unapproved use — to cholestatic liver and bile-duct problems: bile-duct widening, narrowing, obstruction, and sclerosing cholangitis. For repeated dosing it calls for baseline alkaline phosphatase and gamma-glutamyl transferase, then periodic monitoring. Signs of sclerosing cholangitis call for immediate discontinuation and specialist referral.[1]

Long-term use or misuse has been linked to cystitis, reduced bladder capacity, ureteral narrowing or obstruction, hydronephrosis, and kidney problems. The warnings give no rate for supervised depression care. Urinary obstruction or severe lower urinary symptoms call for discontinuation and urgent urologic evaluation.[1]

A 2026 review of 32 longer-term ketamine and esketamine studies did not find a pattern of organ harm accumulating over time, nor a pattern of treatment-caused addiction. But many of those studies had no control group, mixed routes together, and assessed harms inconsistently. “No signal detected” is not “no risk.” The product labeling still governs.[17]

Who may not be a candidate

The injection label carries exactly two contraindications:[1]

1. Known hypersensitivity to ketamine or any ingredient
2. Any situation in which a significant rise in blood pressure would pose a serious hazard

Note what the label does not do: it gives no single blood-pressure number for psychiatric care.

Cardiac and vascular disease, arrhythmia, heart failure, and raised intracranial pressure may change the decision or the monitoring plan. So may airway risk, liver or urinary disease, pregnancy, psychosis, bipolarity, cognitive impairment, and current or past substance-use disorder. These are not all FDA contraindications — some are label warnings, some trial exclusions, some consensus cautions, some pure clinical judgment.[1,21,26]

Institutional thresholds differ. VA documents, for instance, use specific blood-pressure exclusions — but those are institutional protocols, not FDA rules.[26] A good clinic can tell you which source backs each of its exclusions.

How to judge an infusion clinic

Because no federal safety program governs this treatment the way the REMS governs Spravato, the quality floor is whatever the individual clinic decides it is. That makes this list the most practically useful thing on the page.

It is not my invention. The items below are drawn from the ketamine injection label, the CANMAT task force recommendations, the VA national protocol guidance, and the ASKP3 Delphi consensus — the four documents that come closest to a standard of care for this treatment.[1,21,26,29]

A credible clinic can answer all twelve clearly:

1. A qualified clinician confirms the diagnosis, reviews pseudo-resistance, screens medical and psychiatric risk, and obtains informed off-label consent.
2. It names the responsible clinician and the staff present during infusion and recovery.
3. It discloses the exact product and manufacturer — and if sterile compounding is involved, names the pharmacy and explains its safeguards.
4. It records baseline and continuous vital signs, respiration, oxygen saturation, mental state, and adverse events, with appropriate equipment.
5. Staff and ready equipment can manage the airway, oxygenation, ventilation, major blood-pressure changes, arrhythmia, vomiting, and agitation.
6. There is a written emergency-transfer plan.
7. It uses defined physical and mental recovery criteria before discharge, requires safe transportation, and gives written driving limits.
8. It uses validated measures to track depression, function, adverse effects, substance use, mania, psychosis, and suicide risk.
9. Repeated care includes the label’s liver tests plus checks on urinary health, cognition, and substance use.
10. It coordinates medication, therapy, safety planning, and follow-up with your ongoing mental-health team.
11. It has transparent rules for maintenance, intervals, no-benefit, harm, and stopping.
12. It gives a written estimate covering product, professional, facility, monitoring, laboratory, follow-up, and cancellation fees.

Red flags: guaranteed results. Pressure to buy a package before assessment. Take-home IV supplies. No named responsible clinician. No airway plan. No outcome tracking. No connection to your ongoing care. Or the claim that dissociation proves the treatment is working.

IV ketamine compared with Spravato

How to read that table. The regulatory and operational rows are official facts, not efficacy comparisons.

The effectiveness comparison is another matter. It rests almost entirely on observational cohorts, whose authors describe their pooled estimates as associations that are hypothesis-generating and call for large head-to-head randomized trials.[41] Comparing each treatment against its own separate placebo across separate trials is context, not a head-to-head result.

No completed randomized trial supports “better,” “faster,” “stronger,” or “safer” in either direction.[41,42] Given the disclosure at the top of this page, that is exactly the sentence I would most want you to check against the sources yourself.

Practical tradeoffs

In favor of the IV route: precise control of infusion rate, complete delivery into the blood, and the ability to stop mid-infusion if side effects become intolerable. None of that proves greater antidepressant benefit. And an IV is a genuine burden for anyone with difficult vein access or a needle phobia.

Against it: off-label status, protocols that vary between clinics, repeated travel, monitoring and recovery time, the 24-hour driving restriction, uncertain maintenance, likely self-pay cost, and ongoing safety monitoring with repeated use.

The absence of a REMS makes access more flexible. It does not make monitoring optional.

And these are not the only two options on the table. ECT, TMS, medication augmentation, and psychotherapy all fit different situations.[22,45]

Cost, insurance, and access

Access information verified August 23, 2026.

There is no standard U.S. price for off-label IV depression care. A quote may fold together the evaluation, the drug, IV supplies, staff and facility time, monitoring, recovery, labs, and follow-up — and sometimes a prepaid package of future infusions. Ask what is included, and ask what happens to the money if you stop early.

Coverage varies. Aetna’s current public policy, for example, calls IV ketamine for depression experimental, investigational, or unproven. That is one payer’s rule, not a national one.[43] Some VA and other systems cover it under defined criteria.[26]

One academic center listed $550 per infusion as a self-pay price, describing ketamine as not covered by most insurance. That page has since been retired, and the successor Mass General Brigham service page lists no price at all. Treat it as one institution at one point in time — not a national average, and not a coverage promise.[46]

Transportation, missed work, childcare, and repeated lab tests all add cost that no quote will list.

Questions to ask an infusion clinic

1. Who confirms my diagnosis and reviews my treatment history?
2. Why consider off-label IV ketamine before or after ECT, TMS, medication augmentation, or psychotherapy?
3. Which exact injectable product and manufacturer will you use?
4. Is sterile compounding involved, and who prepares it?
5. Who is medically responsible during the infusion and recovery?
6. Which vital signs, respiratory, cardiac, and mental-state measures are continuous?
7. Which airway, oxygen, cardiac, medication, and transfer resources are ready?
8. What are the discharge, ride, and driving rules?
9. How will you track symptoms, function, suicide risk, mania, psychosis, cognition, urinary symptoms, substance use, and adverse events?
10. What baseline and periodic liver tests do you run for repeated treatment?
11. What counts as benefit, relapse, harm, or a reason to stop?
12. How do you coordinate with my prescriber, therapist, and emergency plan?
13. What are all the fees, and what happens to prepaid costs if care ends early?

Related reading

• Spravato (esketamine) for depression: who it is for, what a visit is like, and what the evidence shows
• TMS for depression: benefits, protocols, safety, and what the evidence really shows
• Why antidepressants take time, and how to make the first six weeks count
• Why bipolar disorder gets diagnosed as depression first
• Urgent mental health care: finding the support you need right away

Frequently asked questions

Is IV ketamine FDA approved for depression?

No. Ketamine injection is approved as a general anesthetic. Depression use is off-label, with no FDA-approved psychiatric dose, series, or maintenance schedule.[1]

How quickly might it help?

Trials measured average symptom differences from 40 minutes to four hours, and most often at 24 hours. Not everyone feels better that day.[3,4,5,6]

How many infusions do studies use?

Often two or three weekly for two to four weeks. Protocols vary, and these are research examples rather than an approved schedule.[7,8,9,10]

How long might benefit last?

It varies widely. Many responders in small studies relapsed within days to weeks; some stayed well longer. The best maintenance plan is not known.[9,11,12]

Can it reduce suicidal thoughts?

Some trials found short-term drops in ideation scores. Others were negative or specific to one diagnosis. It has not been shown to prevent attempts or deaths.[13,14,15,16]

Will I be unconscious?

Common psychiatric protocols do not aim for unconsciousness. Sedation, altered awareness, and rare serious respiratory effects can occur — which is why monitoring and rescue readiness are required.[1]

Is this psychedelic-assisted therapy?

Not necessarily. Standard IV treatment does not include therapy during the dosing session. Ketamine-assisted psychotherapy is a separate model with its own separate evidence.

What are the bladder, liver, and cognitive risks?

The label warns of urinary and cholestatic liver or bile-duct injury with repeated exposure, and calls for baseline alkaline phosphatase and gamma-glutamyl transferase followed by periodic testing. Long-term cognitive risk at depression doses is not well measured.[1,17]

Can IV ketamine be addictive?

Yes. It is Schedule III, and misuse, tolerance, physical dependence, and addiction are all possible. The rates in well-monitored depression care have not been established.[1,20]

Does insurance cover it?

Often not. Some current commercial policies, including Aetna’s, call IV ketamine for depression experimental or investigational. Verify your specific plan and every facility, monitoring, and professional fee in writing.[43]

Which is better, IV ketamine or Spravato?

No completed randomized trial answers that. The available comparisons are observational, and the pooled differences were not statistically significant. Approval status, safety framework, route, schedule, access, cost, and your own medical risk probably matter more than a ranking nobody can currently justify.[41,42]

Bottom line

IV racemic ketamine has genuine randomized evidence for short-term symptom relief in selected adults with unipolar treatment-resistant depression. That is a real finding, and it should not be dismissed.

It is also far less certain about maintenance, function, rare harms, suicide prevention, and how it compares with Spravato. Off-label care can be entirely reasonable without being standard — but the absence of an approved protocol means the quality of the clinic is doing work that regulation would otherwise do.

A careful decision needs a verified diagnosis, an honest look at the alternatives, informed consent, label-based monitoring, emergency readiness, measurable goals, coordination with your existing care, and clear rules for benefit, relapse, harm, cost, and stopping.

Educational disclaimer

Disclosure: Inland Psychiatric Medical Group, where I practice, offers Spravato and does not offer IV ketamine. This article covers a treatment we do not provide while we do provide the alternative it is most often compared with.

This article is for education. It does not diagnose any condition, choose a treatment for anyone, or replace the judgment of the clinician who knows your history. Do not start, stop, or change any medication without your prescriber. If there is imminent danger, or you cannot keep yourself or someone else safe, call 911 or go to the nearest emergency department. In the United States, call or text 988, or chat at 988lifeline.org, for any mental-health crisis.[30] Every regulatory, numeric, and citation claim in this article was verified against primary FDA and journal sources on August 23, 2026. Labels, payer policies, and clinic practices change; confirm current status before acting on anything here.

References

1. Par Health USA, LLC. KETALAR (ketamine hydrochloride) injection — full prescribing information. Revised March 2026. Hosted on DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063. Accessed 2026-08-23.
2. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. PMID 10686270. doi:10.1016/S0006-3223(99)00230-9.
3. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. PMID 16894061. doi:10.1001/archpsyc.63.8.856. ClinicalTrials.gov NCT00088699.
4. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. PMID 23982301. doi:10.1176/appi.ajp.2013.13030392.
5. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25(7):1592-1603. PMID 30283029. doi:10.1038/s41380-018-0256-5. ClinicalTrials.gov NCT01920555.
6. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2026;83(7):714-731. PMID 42090166. doi:10.1001/jamapsychiatry.2026.0612.
7. Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816-826. PMID 27056608. doi:10.1176/appi.ajp.2016.16010037. ClinicalTrials.gov NCT01627782.
8. Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176(5):401-409. PMID 30922101. doi:10.1176/appi.ajp.2018.18070834. ClinicalTrials.gov NCT01945047.
9. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256. PMID 22840761. doi:10.1016/j.biopsych.2012.06.022.
10. Jelovac A, McCaffrey C, Terao M, et al. Serial ketamine infusions as adjunctive therapy to inpatient care for depression: the KARMA-Dep 2 randomized clinical trial. JAMA Psychiatry. 2025;82(12):1216-1224. PMID 41123905. doi:10.1001/jamapsychiatry.2025.3019. ClinicalTrials.gov NCT04939649.
11. Smith-Apeldoorn SY, et al. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907-921. PMID 36244360. doi:10.1016/S2215-0366(22)00317-0.
12. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145. PMID 19897179. doi:10.1016/j.biopsych.2009.08.038.
13. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327-335. PMID 29202655. doi:10.1176/appi.ajp.2017.17060647. ClinicalTrials.gov NCT01700829.
14. Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. PMID 35110300. doi:10.1136/bmj-2021-067194. ClinicalTrials.gov NCT02299440.
15. Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516-524. PMID 30286416. doi:10.1016/j.jad.2018.09.037.
16. Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-158. PMID 28969441. doi:10.1176/appi.ajp.2017.17040472.
17. Wasolua TT, Hardy MS, Bommersbach TJ, McIntyre RS, Rhee TG. A systematic review of long-term safety outcomes of ketamine and esketamine in patients with treatment-resistant depression. Psychother Psychosom. Published online August 17, 2026. PMID 42611840.
18. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621-660. doi:10.1124/pr.117.015198. https://pmc.ncbi.nlm.nih.gov/articles/PMC6020109/
19. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs “off label.” https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label. Accessed 2026-08-23.
20. Electronic Code of Federal Regulations. 21 CFR 1308.13(c)(7) — Schedule III, ketamine. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.13. Accessed 2026-08-23.
21. Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder. Can J Psychiatry. 2021;66(2):113-125. PMID 33174760. doi:10.1177/0706743720970860. https://pmc.ncbi.nlm.nih.gov/articles/PMC7918868/
22. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf. Accessed 2026-08-23.
23. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793-802. PMID 20679587. doi:10.1001/archgenpsychiatry.2010.90. ClinicalTrials.gov NCT00088699.
24. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801-811. PMID 29532791. doi:10.1038/mp.2017.255.
25. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059-1077. PMID 27028535. doi:10.1007/s40262-016-0383-6. https://pubmed.ncbi.nlm.nih.gov/27028535/
26. U.S. Department of Veterans Affairs, Pharmacy Benefits Management Services, National Formulary Committee, and Office of Mental Health. Ketamine infusion for treatment resistant depression and severe suicidal ideation: national protocol guidance. October 2025. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Ketamine_Infusion_for_Treatment_Resistant_Depression_Rev_Oct_2025.pdf. Accessed 2026-08-23.
27. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al. Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(10):808-831. PMID 34170315. doi:10.1093/ijnp/pyab039.
28. Lu A, Xu H, Le GH, et al. Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms? Eur Psychiatry. 2026;69:e24. PMID 41607072. doi:10.1192/j.eurpsy.2026.10157.
29. Mathai DS, Cluck M, Aslam AM, et al. Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). J Affect Disord. 2026;411:121970. PMID 42144140. doi:10.1016/j.jad.2026.121970.
30. 988 Suicide & Crisis Lifeline. Get Help. https://988lifeline.org/get-help/. Accessed 2026-08-23.
31. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946. PMID 22297150. doi:10.1016/j.biopsych.2011.12.010.
32. Janssen Pharmaceuticals, Inc. SPRAVATO (esketamine) nasal spray — full prescribing information. Prescribing information revised March 2026. Hosted on DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed. Accessed 2026-08-23.
33. U.S. Food and Drug Administration. Compounding risk alerts. https://www.fda.gov/drugs/human-drug-compounding/compounding-risk-alerts. Accessed 2026-08-23.
34. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) Document: SPRAVATO (esketamine) REMS. NDA 211243; most recent REMS update June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/rems/Spravato_2026_06_24_REMS_Document.pdf. Accessed 2026-08-23.
35. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428-438. PMID 31109201. doi:10.1176/appi.ajp.2019.19020172.
36. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. PMID 31290965. doi:10.1093/ijnp/pyz039.
37. Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression — TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121-141. PMID 31734084. doi:10.1016/j.jagp.2019.10.008.
38. Janik A, Qiu X, Lane R, et al. Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2025;82(9):877-887. PMID 40601310. doi:10.1001/jamapsychiatry.2025.1317.
39. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903. PMID 31166571. doi:10.1001/jamapsychiatry.2019.1189.
40. Zaki N, Chen LN, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. 2025;28(6):pyaf027. PMID 40319349. doi:10.1093/ijnp/pyaf027.
41. Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L, et al. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Ther Adv Psychopharmacol. 2025;15:20451253251394127. PMID 41244961. doi:10.1177/20451253251394127.
42. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemp Clin Trials. 2026;164:108273. PMID 41780747. doi:10.1016/j.cct.2026.108273. ClinicalTrials.gov NCT06713616 — recruiting, no results posted.
43. Aetna. Ketamine for the Treatment of Depression and Other Selected Indications. Medical Clinical Policy Bulletin Number 0938. https://www.aetna.com/cpb/medical/data/900_999/0938.html. Accessed 2026-08-23. One payer’s policy, cited as an example. It does not establish coverage for any individual member.
44. Aetna. Esketamine (Spravato) — Clinical Policy Bulletin 0950. https://www.aetna.com/cpb/medical/data/900_999/0950.html. Accessed 2026-08-23.
45. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641-687. PMID 38711351. doi:10.1177/07067437241245384.
46. Massachusetts General Hospital. Ketamine Clinic for Depression — treatment options and cost. Archived February 18, 2026; the page has since been removed and redirects to a Mass General Brigham service page carrying no pricing. https://web.archive.org/web/20260218003156/https://www.massgeneral.org/psychiatry/treatments-and-services/ketamine-clinic-for-depression. Accessed 2026-08-23. One academic center’s published pricing at one point in time, not a national average.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.